A Series A funding round yielded $42 million for cell therapy developer Vor Biopharma. Vor, which develops targeted immunotherapies using engineered hematopoietic stem cells, will use the funds to advance its acute myeloid leukemia candidate toward the clinical trial stage.
Funding round raises $42M for cell therapy developer
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.